Brain-derived neurotrophic factor and the plasticity of the mesolimbic dopamine pathway

International Review of Neurobiology

Volumn 59, Issue , 2004, Pages 425-444

  Guillin, Oliver ^a   Griffon, Nathalie ^a   Diaz, Jorge ^b   Le Foll, Bernard ^a   Bezard, Erwan ^c   Gross, Christian ^c   Lammers, Chris ^a   Stark, Holger ^d   Carroll, Patrick ^e   Schwartz, Jean Charles ^a,b   Sokoloff, Pierre ^a  

^a CENTRE PAUL BROCA   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CNRS   (France)

^d UNIVERSITY OF BONN   (Germany)

^e INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DRD3 PROTEIN, HUMAN; LEVODOPA;

ANIMAL; CYTOLOGY; DENERVATION; DEPRESSION; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; LIMBIC SYSTEM; METABOLISM; METHODOLOGY; NERVE CELL PLASTICITY; PHYSIOLOGY; REVIEW; SCHIZOPHRENIA; STRESS;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; DENERVATION; DEPRESSION; DOPAMINE; DOPAMINE AGENTS; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; LEVODOPA; LIMBIC SYSTEM; NEURONAL PLASTICITY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; STRESS;

EID: 2342635828     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(04)59016-5     Document Type: Article

References (83)

1. Altar, C. A., Cai, N., Bliven, T., Juhasz, M., Conner, J. M., Acheson, A. L., Lindsay, R. M., and Wiegand, S. J. (1997). Anterograde transport of brain-derived neurotrophic factor and its role in the brain. Nature 389, 856-860.
2. Altar, C. A., and Di Stefano, P. S. (1998). Anterograde transport of neurotrophins in the nervous systems. Trends Neurosci. 21, 433-437.
3. Barkai, A. I., Durkin, M., and Nelson, H. D. (1990). Localized alterations of dopamine receptor binding in rat brain by repeated electroconvulsive shock: An autoradiographic study. Brain Res. 529, 208-213.
4. Berendse, H. W., Galis-de-Graaf, Y., and Groenewegen, H. J. (1992). Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J. Comp. Neurol. 316, 314-347.
5. Bezard, E., Brotchic, J., and Gross, C. (2001). Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies. Nature Rev. Neurosci. 2, 577-588.
6. Bezard, E., Ferry, S., Mach, U., Stark, H., Leriche, L., Boraud, T., Gross, C., and Sokoloff, P. (2003). Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nature Med. 6, 762-767.
7. Blum, R., Kafitz, K. W., and Konnerth, A. (2002). Neurotrophin-evoked depolarization requires the sodium channel Na(V)1.9. Nature 419, 687-693.
8. 3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA 94, 3363-3367.
9. Burns, R. S., Chuieh, C. G., Markey, S. P., Ebert, M. H. Jacowitz, D. M., and Kopin, I. J. (1983). A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substancia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA 80, 4546-4550.
10. Cabelli, R.J., Shelton, D. L., Segal, R. A., and Shatz, C. J. (1997). Blockade of endogenous ligands of TrkB inhibits formation of ocular dominance columns. Neuron 19, 63-76.
11. Carroll, P., Lewin, G. R., Koltzenburg, M., Toyka, K. V., and Thoenen, H. (1998). A role for BDNF in mechanosensation. Nature Neurosci. 1, 5-6.
12. Chen, B., Dowlatshahi, D., McQueen, G. M., Wang, J.-F., and Young, L. T. (2001). Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol. Psychiat. 50, 260-265.
13. Childress, A. R., Mozley, P. D., McElgin, W.J. F., Reivich, M., and O'Brien, G. P. (1999). Limbic activation during cue-induced cocaine craving. Am. J. Psychia. 156, 11-18.
14. Cole, D. G., Kobierski, L. A., Konradi, C., and Hyman, S. E. (1994). 6-Hydroxydopamine lesions of the rat substamia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons. Proc. Natl. Acad. Sci. USA 91, 9631-9635.
15. Conner, J., and Lauter, J. C. (1997). Distribution of brain-derived neurotrophic factor (BDNF) protein and mRNA in the normal adult rat CNS: Evidence for anterograde axonal transport. J. Neurosci. 17, 2295-2313.
16. Cotzias, G., Papavasiliou, P., and Gellene, R. (1969). Modification of Parkinsonism: Chronic treatment with L-dopa. N. Engl. J. Med. 280, 337-345.
17. 3 receptor in the rat brain. Neuroscience 65, 731-745.
18. 3 receptor mRNA in proliferative zones during embryonic development of the rat brain. J. Neurosci. 17, 4282-4292.
19. Di Chiara, G., and Imperato, A. (1988). Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. USA 85, 5274-5278.
20. Dubertret, C., Gorwod, P., Ades, J., Feingold, J., Schwartz, J.-C., and Sokoloff, P. (1998). A meta-analysis of DRD3 gene and schizophrenia: Ethnic heterogeneity and significant association in Caucasians. Am. J. Med. Genet. 81, 318-322.
21. Emfors, P., Lee, K.-F., and Jaenisch, R. (1994). Mice lacking brain-derived neurotrophic factor develop with sensory deficits. Nature 368, 147-150.
22. Figurov, A., Pozzo-Miller, L. D., Olafsson, P., Wang, T., and Lu, B. (1996). Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381, 706-709.
23. Fishbum, C. S., David, C., Carmon, S., and Fuchs, S. (1994). The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain. FEBS Lett. 339, 63-66.
24. 3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J. Neurosci. 16, 2020-2026.
25. Fontana, D. J., Post, R. M., and Pert, A. (1993). Conditioned increases in mesolimbic dopamine overflow by stimuli associated with cocaine. Brain Res. 629, 31-39.
26. Goldberg, S. R., and Gardner, M. L. (1981). Second-order schedules: Extended sequences of behavior controlled by brief environmental stimuli associated with drug self-administration. NIDA Res. Monogr. 37, 241-270.
27. 3 receptor expression and triggers behavioural sensitization. Nature 411, 86-89.
28. 3 receptors and use of antipsychotics in patients with schizophrenia. Arch. Gen. Psychiat. 54, 225-232.
29. Horger, B. A., Iyasere, C. A., Berhow, M. T., Messer, C. J., Nestler, E. J., and Taylor, J. R. (1999). Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. J. Neurosci. 19, 4110-4122.
30. Hornykiewicz, O. (1963). Die topishe Lokalisation und das verhalten von noradrenalin und dopamin (3-hydroxytyramin) in der substantia nigra des normalen und Parkinson-kranken menschen. Wien. Klin. Wschr. 75, 309-312.
31. 1 dopamine receptor in rat brain reveals its axonal transport, pre- and post-synaptic localization, and prevalence in the basal ganglia, limbic system and thalamic reticular nucleus. Proc. Natl. Acad. Sci. USA 89, 11988-11992.
32. Huang, Z. J., Kikwood, A., Pizzorusso, T., Porciatti, V., Morales, B., Bear, M. F., Maffei, L., and Tonegawa, S. (1999). BDNF regulates the maturation of the inhibition of the critical period of plasticity in mouse visual cortex. Cell 98, 739-755.
33. Imperato, A., Mulas, A., and Di Chiara, G. (1986). Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur. J. Pharmacol. 132, 337-338.
34. Joyce, J., Ryoo, H., Beach, T., Caviness, J. N., Stacy, M., Gurevich, E. V., Reiser, M., and Adler, C. H. (2002). Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: Role of D3 and not D2 receptors. Brain Res. 955, 138-152.
35. Kafitz, K. W., Rose, C. R., Thoenen, H., and Konnerth, A. (1999). Neurotrophin-evoked rapid excitation through TrkB receptors. Nature 401, 918-921.
36. Kerr, B. J., Bradbury, E. J., Bennett, D. L., Trivedi, P. M., Dassan, P., French, J., Shelton, D. B., McMahon, S. B., and Thompson, S. W. (1999). Brain-derived neurotrophic factor modulates nociceptive sensory inputs and NMDA-evoked responses in the rat spinal cord. J. Neurosci. 19, 5138-5148.
37. Korte, M., Carroll, P., Wolf, E., Brem, G., Thoenen, H., and Bonhoeffer, T. (1995). Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Nat. Acad. Sci. USA 92, 8856-8860.
38. Kovalchuk, Y., Hanse, E., Kafitz, K. W., and Konnerth, A. (2002). Postsynaptic induction of BDNF-mediated long-term potentiation. Science 295, 1651-1653.
39. 3 receptor gene expression as a common effect of chronic antidepressant treatments. Mol. Psychiat. 5, 378-388.
40. Laufer, R., and Changeux, J.-P. (1989). Activity-dependent regulation of gene expression in muscle and neuronal cells. Mol. Neurobiol. 3, 1-53.
41. Le Foll, B., Francès, H., Diaz, J., Schwartz, J.-C., and Sokoloff, P. (2002). Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur. J. Neurosci. 15, 2016-2026.
42. Le Foll, B., Schwartz, J.-C., and Sokoloff, P. (2003). Inhibition of nicotine conditioning by dopamine D3 receptor ligands. Mol. Psychiat. 8, 225-230.
43. Leriche, L., Schwartz, J., and Sokoloff, P. (2003). The dopamine D(3) receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 45, 174-181.
44. 3H]-hydroxy-N,N di-n-propyl-2- aminotetralin. Proc. Natl. Acad. Sci. USA 89, 8155-8159.
45. 3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl. Acad. Sci. USA 92, 1719-1723.
46. Linnarsson, S., Bjorklund, A., and Emfors, P. (1997). Learning deficit in BDNF mutant mice. Eur. J. Neurosci. 9, 2581-2587.
47. Lohof, A. M., Ip, N. Y., and Poo, M. M. (1993). Potentiation of developing neuromuscular synapses by the neurotrophin NT-3 and BDNF. Nature 363, 350-353.
48. Minichiello, L., Korte, M., Wolfer, D., Kuhn, R., Unsicker, K., Cestari, V., Rossi-Arnaud, C., Lipp, H. P., Bonhoeffer, T., and Klein, R. (1999). Essential role for TrkB receptors in hippocampus-mediated learning. Neuron 24, 401-414.
49. Mirenowicz, J., and Schultz, W. (1996). Preferential activation of midbrain dopamine neurons by appetitive rather than aversive stimuli. Nature 379, 449-451.
50. Nibuya, M., Morinobu, S., and Duman, R. S. (1995). Regulation of BDNF and TrkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J. Neurosci. 15, 7539-7547.
51. Nomikos, G. G., Zis, A. P., Damsma, G., and Fibiger, H. C. (1991). Electroconvulsive shock produces large increases in interstitial concentrations of dopamine in the rat striatum: An in vivo microdialysis study. Neuropychopharmacology 4, 65-69.
52. O'Brien, C., Childress, A., McLellan, A., and Ehrman, R. (1992a). Classical conditioning in drug-dependent humans. Ann. N. Y. Acad. Sci. 654, 400-415.
53. O'Brien, C. P., Childress, A. R., McMellan, A. T., and Ehrman, R. A. (1992b). A learning model of addiction. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 70, 157-177.
54. Patterson, S. L., Abel, T., Deuel, T. A. S., Martin, K. C., Rose, J. C., and Kandel, E. R. (1996). Recombinant BDNF rescues deficits in basal synaptic transmission and hippocampal LTP in BDNF knockout mice. Neuron 16, 1137-1145.
55. Pennartz, C. M., Groenewegen, H. J., and Lopes da Silva, F. H. (1994). The nucleus accumbens as a complex of functionally distinct neuronal ensembles: An integration of behavioural, electrophysiological and anatomical data. Prog. Neurobiol. 42, 719-761.
56. 3 receptor agonist. Nature 400, 371-375.
57. Robinson, T., and Berridge, K. (2001). Incentive-sensitization and addiction. Addiction 96, 103-114.
58. 2 receptor is elevated in the striatum of Parkinson's disease. Mov. Disord. 13, 788-797.
59. Schwartz, J. C., Costentin, J., Martres, M. P., Protais, P., and Baudry, M. (1978). Modulation of receptor mechanisms in the CNS: Hyper- and hyposensitivity to catecholamines. Neuropharmacology 17, 665-685.
60. 3 receptor in schizophrenia and antipsychotic drug actions. Brain. Res. Rev. 31, 277-287.
61. Seroogy, K. B., Lundgren, K. H., Tran, T. M. D., Guthrie, K. M., Isackson, P. J., and Gall, C. (1994). Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophin factor and neurotrophin-3 mRNAs. J. Comp. Neurol. 342, 321-334.
62. Shich, P. B., Hu, S. C., Bobb, K., Timmusk, T., and Ghosh, A. (1998). Identification of a signaling pathway involved in calcium regulation of BDNF expression. Neuron 20, 727-740.
63. Shimizu, E., Hashimoto, K., Okamura, N., et al. (2003). Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol. Psychiat. 54, 70-75.
64. Shirayama, Y., Chen, A., Nakagawa, S., Russel, D. S., and Duman, R. S. (2002). Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22, 3251-3261.
65. Smith, M. A., Makino, S., Kvetnansky, R., and Post, R. M. (1995). Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J. Neurosci. 15, 1768-1777.
66. Smith, S. E., and Sharp, T. (1997). Evidence that the enhancement of dopamine function by repeated electroconvulsive shock requires concomitant activation of D1-like and D2-like receptors. Psychopharmacology 133, 77-84.
67. 2 receptor. Eur. J. Phamacol. Mol. Pharmacol. Sect. 225, 331-337.
68. 3 receptor and drug addiction. Neurotoxicity Res. 3, 433-141.
69. 3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J. Neurosci. 16, 6100-6106.
70. 3 dopamine receptor mRNA is widely expressed in the human brain. Brain Res. 779, 58-74.
71. Takahashi, M., Shirakawa, O., Toyooka, K., et al. (2000). Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol. Psychiat. 5, 293-300.
72. 2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 20, 709-726.
73. Tarazi, F. I., Florijn, W. J., and Creese, I. (1997). Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment. Neuroscience 78, 985-996.
74. Thoenen, H. (1995). Neurotrophins and neuronal plasticity. Science 270, 593-598.
75. Vicario-Abejon, C., Collin, C., McKay, R. D. G., and Segal, M. (1998). Neurotrophins induce formation of functional excitatory and inhibitory synapses between cultured hippocampal neurons. J. Neurosci. 18, 7256-7271.
76. von Bartheld, C. S., Byers, M. R., Williams, R., and Bothwell, M. (1996). Anterograde transport of neurotrophins and axodendritic transfer in the developing visual system. Nature 379, 830-833.
77. Weber, B., Schlicker, E., Sokoloff, P., and Stark, H. (2001). Identification of the dopamine autoreceptor in the guinea-pig retina as D2 receptor using novel subtype-selective antagonists. Br. J. Pharmacol. 133, 1243-1248.
78. Weinberger, D. R. (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiat. 44, 660-669.
79. Whitelaw, R. B., Markou, A., Robbins, T. W., and Everitt, B. J. (1996). Excitotoxic lesions of the basolateral amygdala impair the acquisition of cocaine-seeking behaviour under a second-order schedule of reinforcement. Psychopharmacology (Berl.) 127, 213-224.
80. 3 receptor gene and schizophrenia. Mol. Psychiat. 3, 141-149.
81. Willner, P. (1997). The mesolimbic dopamine system as a target for rapid antidepressant action. Int. Clin. Psychopharmacol. 12, S7-S14.
82. Willner, P., and Sheel-Krüger, J. (1991). "The Mesolimbic Dopamine System: From Motivation to Action." Wiley, Chichester.
83. Zahm, D. S., and Brog, J. S. (1992). On the significance of subterritories in the "accumbens" part of the rat ventral striatum. Neuroscience 50, 751-767.